Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.81 |
| ▸ | MMP13 | P45452 | 15/20 | 0.53 |
| ▸ | MMP9 | P14780 | 5/20 | 0.45 |
| ▸ | MMP2 | P08253 | 4/20 | 0.45 |
| ▸ | MMP3 | P08254 | 3/20 | 0.45 |
| ▸ | MMP8 | P22894 | 3/20 | 0.45 |
| ▸ | MMP14 | P50281 | 2/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25130 | 0.92 | MMP1 (0.96) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6813051 | 0.91 | MMP1 (0.94) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL26986 | 0.90 | MMP1 (1.00) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6813091 | 0.89 | MMP1 (0.76) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL20885005 | 0.87 | MMP1 (0.73) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6691684 | 0.87 | MMP1 (0.79) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL3914710 | 0.84 | MMP1 (0.78) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6876444 | 0.83 | MMP1 (0.81) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL26434 | 0.83 | MMP1 (0.83) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL4940266 | 0.83 | MMP1 (0.67) | MMP1MMP13MMP9MMP8MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105409-A9 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2019-04-11 | — | — | US | disclosed |
| US-20140286866-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2014-09-25 | — | — | US | disclosed |
| US-20140286866-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2014-09-25 | — | — | US | disclosed |
| US-20120269727-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2012-10-25 | — | — | US | disclosed |
| US-20120269727-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | GE HEALTHCARE AS (NO) | 2012-10-25 | — | — | US | disclosed |
| US-20080095704-A1 | A polyoxyethylene glycol having a molecular weight of < 3000 Da and 2-50 ethylene glycol units, an imageable moiety anda non-peptidic vector moiety provided that the vector does not have affinity for the Angiotensin II receptor; enhanced contrast; tomography (SPECT); PET sccans; MRIs | GE HEALTHCARE AS (NO) | 2008-04-24 | — | — | US | disclosed |
| US-20080095704-A1 | A polyoxyethylene glycol having a molecular weight of < 3000 Da and 2-50 ethylene glycol units, an imageable moiety anda non-peptidic vector moiety provided that the vector does not have affinity for the Angiotensin II receptor; enhanced contrast; tomography (SPECT); PET sccans; MRIs | GE HEALTHCARE AS (NO) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080095704-A1 | A polyoxyethylene glycol having a molecular weight of < 3000 Da and 2-50 ethylene glycol units, an imageable moiety anda non-peptidic vector moiety provided that the vector does not have affinity for the Angiotensin II receptor; enhanced contrast; tomography (SPECT); PET sccans; MRIs | AGTR1, AGTR2, AVPR1A | MMP1 342/4885MMP13 416/4885MMP9 527/4885 |
| US-20190105409-A9 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | SLC10A1, SLC10A2, SLC19A1 | MMP1 1627/4885MMP13 1758/4885MMP9 2338/4885 |
| US-20140286866-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | SLC10A1, SLC10A2, SLC19A1 | MMP1 1627/4885MMP13 1758/4885MMP9 2338/4885 |
| US-20120269727-A1 | IMAGING AGENTS WITH IMPROVED PHARMACOKINETIC PROFILES | SLC10A1, SLC10A2, SLC19A1 | MMP1 1627/4885MMP13 1758/4885MMP9 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.